医学
风险评估
风险分析(工程)
人口
批判性评价
文档
重症监护医学
特定风险
代理终结点
病理
环境卫生
替代医学
计算机科学
金融经济学
经济
程序设计语言
计算机安全
作者
Mark Andrew Hlatky,Philip Greenland,Donna K. Arnett,Christie Mitchell Ballantyne,Michael H. Criqui,Mitchell S.V. Elkind,Alan S. Go,Frank E. Harrell,Yuling Hong,Barbara V. Howard,Virginia J. Howard,Priscilla Y. Hsue,Christopher M. Kramer,Joseph P. McConnell,Sharon‐Lise T. Normand,Christopher J. O’Donnell,Sidney C. Smith,Peter W.F. Wilson
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2009-04-13
卷期号:119 (17): 2408-2416
被引量:1248
标识
DOI:10.1161/circulationaha.109.192278
摘要
There is increasing interest in utilizing novel markers of cardiovascular disease risk, and consequently, there is a need to assess the value of their use. This scientific statement reviews current concepts of risk evaluation and proposes standards for the critical appraisal of risk assessment methods. An adequate evaluation of a novel risk marker requires a sound research design, a representative at-risk population, and an adequate number of outcome events. Studies of a novel marker should report the degree to which it adds to the prognostic information provided by standard risk markers. No single statistical measure provides all the information needed to assess a novel marker, so measures of both discrimination and accuracy should be reported. The clinical value of a marker should be assessed by its effect on patient management and outcomes. In general, a novel risk marker should be evaluated in several phases, including initial proof of concept, prospective validation in independent populations, documentation of incremental information when added to standard risk markers, assessment of effects on patient management and outcomes, and ultimately, cost-effectiveness.
科研通智能强力驱动
Strongly Powered by AbleSci AI